Effect of carvedilol versus metoprolol CR/XL on mortality in patients with heart failure treated with cardiac resynchronization therapy: A COX multivariate regression analysis

American Journal of Therapeutics

Volumn 20, Issue 3, 2013, Pages 247-253

  Shen, Xuedong ^a   Nair, Chandra K ^a   Aronow, Wilbert S ^b   Hee, Tom ^a   Esterbrooks, Dennis J ^a  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Beta blockers; Cardiac resynchronization therapy; Carvedilol; Heart failure; Metoprolol CR Xl

Indexed keywords

CARVEDILOL; METOPROLOL;

AGE; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENCE; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CARBAZOLES; CARDIAC RESYNCHRONIZATION THERAPY; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METOPROLOL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84880067813     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181f2abb3     Document Type: Article

References (17)

1. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343-1382.
2. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet. 1999;353:2001-2007.
4. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group. Developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
5. Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol. 2002;40:1615-1622.
6. Perez de Isla L, Ortiz Oficialdegui P, Florit J, et al. RAVE usefulness of clinical, electrocardiographic, and echocardiographic parameters to detect cardiac asynchrony in patients with left ventricular dysfunction secondary to ischemic or nonischemic heart disease. J Am Soc Echocardiogr. 2006;19:1338-1344.
7. Pérez de Isla L, Florit J, Garcia-Fernandez MA, et al. Prevalence of echocardiographically detected ventricular asynchrony in patients with left ventricular systolic dysfunction. J Am Soc Echocardiogr. 2005;18:850-859.
8. Sohn D-W, Chai I-H, Lee D-J, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997;30:474-480.
9. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. Am J Soc Echocardiogr. 2003;16:777-802.
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension. 2007;25:1105-1187.
11. American Diabetes Association. Clinical practice recommendations 1999 (position statement). Diabetes Care. 1999; 22(Suppl 1):S1-S114.
12. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130:461-470.
13. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
14. Yu CM, Fung JW, Zhang Q, et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation. 2004;110: 66-73.
15. Bleeker GB, Kaandorp TAM, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969-976.
16. Gasparini M, Mantica M, Galimberti P, et al. Is the outcome of cardiac resynchronization therapy related to the underlying etiology? PACE. 2003;26:175-180.
17. Shen X, Aronow WS, Nair CK, et al. Are the extent, location and score of segmental wall motion abnormalities related to cardiac resynchronization therapy response? Echocardiography. 2009;26:1136-1145.